Skip to content

A multicenter, randomized controlled clinical trial on the effectiveness and safety of pure magnesium tissue-guided membrane application in alveolar bone defect repair

A multicenter, randomized controlled clinical trial on the effectiveness and safety of pure magnesium tissue-guided membrane application in alveolar bone defect repair

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500107169
Enrollment
Unknown
Registered
2025-08-05
Start date
2026-02-05
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vertical bone defect with a vertical height of =10mm

Interventions

Experimental group:Bone powder + single-layer pure magnesium film (+ pure magnesium screws)
Control group:Bone powder + single-layer collagen membrane

Sponsors

Hospital of Stomatology Wuhan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-65 years old (including both 18 and 65 years); gender is not limited; 2. Imaging examination confirms that the height of alveolar bone defect >=10mm; 3. There must be an adjacent tooth at the site of alveolar bone defect; 4. The patient can understand the purpose of the trial, voluntarily participate in the trial, and sign the 'Informed Consent Form'.

Exclusion criteria

Exclusion criteria: 1. Individuals allergic to magnesium or magnesium alloys; 2. Those known to be allergic to bovine or porcine-derived implants or who refuse them; 3. Patients requiring the use of autologous bone or other bone substitutes not provided in non-clinical trials; 4. Those with a history of head and neck radiotherapy or chemotherapy, currently undergoing such treatment, or planning to receive it; 5. Those currently receiving or within the past three months have received medications that may affect bone metabolism or have abnormal bone metabolism; 6. Patients with osteoporosis or osteomalacia; 7. Those with acute or chronic inflammation at the repair site; 8. Those with metal dentures, porcelain teeth, or other devices in adjacent teeth that could cause artifacts on imaging tests; 9. Smokers who average more than 5 cigarettes per day; 10. Alcoholics, drug addicts, or those addicted to other substances; 11. Individuals with severe cardiovascular or immunological disorders, serious blood diseases (such as leukemia); 12. Those with abnormal coagulation function or long-term use of anticoagulants (activated partial thromboplastin time, prothrombin time, thrombin time >= 1.5 times the upper limit of normal values); 13. Diabetic patients with fasting blood glucose >= 8.0mmol/L or systolic pressure >= 160mmHg and/or diastolic pressure >= 100mmHg; 14. Those with liver or kidney dysfunction (aspartate aminotransferase, alanine aminotransferase, creatinine >= 1.5 times the upper limit of normal values); 15. Those with thyroid dysfunction; 16. Pregnant women, breastfeeding mothers, or those planning to become pregnant within 6 months; 17. Those who have participated in or are currently participating in other clinical trials within the past 3 months; 18. Those deemed unsuitable for inclusion by the researcher.

Design outcomes

Primary

MeasureTime frame
Surgery success rate;Incidence of adverse events;

Secondary

MeasureTime frame
Imaging new bone volume percentage;

Countries

China

Contacts

Public ContactZhe Shao

Hospital of Stomatology Wuhan University

shaozhe@whu.edu.cn+86 139 0863 9687

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 4, 2026